Pulmonary vascular disease & thromboembolism

Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism

CirculationPublished Proteomic association study in prospective cohorts with Mendelian randomisation

Authors' conclusion

We identified several novel plasma proteins for VTE that reflect biological processes outside established VTE pathophysiology, including extracellular matrix regulation, immunity, immune-vascular endothelium interactions, and vascular senescence.

Study context

Population
Participants of ARIC, CHS, MESA and HUNT cohorts followed for incident noncancer venous thromboembolism (VTE) (max 10 to 29 years)
Participants
20,737 participants1,371 incident noncancer VTEs
Outcome
Incident noncancer VTE; association of baseline plasma proteins (≈5000 to 7000) with VTE risk
Follow-up
Maximum of 10 to 29 years
Methodological details4 longitudinal cohorts (ARIC, CHS, MESA, HUNT), discovery meta-analysis with replication in HUNT, external replication in UK Biobank (Olink), aptamer-based proteomics (SomaScan), Cox proportional hazards regression, Mendelian randomization
  • 4 longitudinal cohorts (ARIC, CHS, MESA, HUNT)
  • Discovery meta-analysis with replication in HUNT
  • External replication in UK Biobank (Olink)
  • Aptamer-based proteomics (SomaScan)
  • Cox proportional hazards regression
  • Mendelian randomization

Main finding

As reported in the abstract

Proteins associated with incident noncancer VTE

Proteins exceeding FDR-adjusted P<0.05 (unadjusted P<6.5×10-4) in discovery meta-analysis and replicated in HUNT at unadjusted P<0.05

23

Proteins new to VTE

15

New proteins exceeding Bonferroni threshold in HUNT (transgelin, SVEP1, TIMP4)

3

Observational data: associations, not effects.

Further findings

External replication in UK Biobank (Olink), 783 incident noncancer VTEs among 39 097 participants

Top VTE proteins available on UKB Olink panel
16
Replicated in UKB after Bonferroni correction
11

Mendelian randomization (MR) analysis of the 15 new proteins

Significant evidence for possible causal role of TIMD4
Bonferroni-corrected P<0.05
Suggestive evidence for TIMP4 and CST3 (cystatin-c)
unadjusted P<0.05
MR direction opposite to proteomics for TIMP4 and TIMD4, consistent for CST3

Original publication

Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. Circulation. Published 16 February 2026. doi:10.1161/circulationaha.125.074493

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.